Degarelix | List of Frontiers open access articles

Review

Published on 14 Jun 2021

Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies

in Cancer Endocrinology

Alessandro Sciarra
Gian Maria Busetto
Stefano Salciccia
Francesco Del Giudice
Martina Maggi
Felice Crocetto
Matteo Ferro
Ettore De Berardinis
Roberto Mario Scarpa
Francesco Porpiglia

Frontiers in Endocrinology

doi 10.3389/fendo.2021.695170

7,201 views
25 citations

Systematic Review

Accepted on 16 Feb 2026

Cost-effectiveness of degarelix versus LHRH agonists in prostate cancer: a systematic review

in Health System Economics and Financing

Wei Wang
Xiaoyan You
Yang Liu
Xianying Wang

Frontiers in Health Services

Original Research

Published on 18 Jul 2022

Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis

in Health Economics

Jianzhou Yan
Caiyun Li
Xuefang Zhang
Luyan Cheng
Ruilin Ding
Lingli Zhang

Frontiers in Public Health

doi 10.3389/fpubh.2022.942800

6,060 views
5 citations

Original Research

Published on 01 Mar 2018

A Proof-of-Concept Clinical Trial of A Single Luteal Use of Long-Acting Gonadotropin-Releasing Hormone Antagonist Degarelix in Controlled Ovarian Stimulation for In Vitro Fertilization: Long Antagonist Protocol

in Reproduction

Evangelos G. Papanikolaou
Hakan Yarali
Evi Timotheou
Michael Grynberg
Odysseas Zafeiratis
Herman Tournaye
Robert Najdecki

Frontiers in Endocrinology

doi 10.3389/fendo.2018.00025

7,241 views
8 citations

Review

Published on 01 Oct 2025

Comparing the risk of cardiovascular disease between degarelix and gonadotropin-releasing hormone agonists:a systematic review and meta-analysis

in Cancer Molecular Targets and Therapeutics

Wencong Liu
Zhenyu Liu
Liangdong Song
Huixuan Zhu
Yu Luo
Jindong Zhang
Shuai Su
Delin Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1523794

2,836 views

Original Research

Published on 03 Mar 2020

Gender Disparity Impacts on Thymus Aging and LHRH Receptor Antagonist-Induced Thymic Reconstitution Following Chemotherapeutic Damage

in T Cell Biology

Michael Ly Hun
Kahlia Wong
Josephine Rahma Gunawan
Abdulaziz Alsharif
Kylie Quinn
Ann P. Chidgey

Frontiers in Immunology

doi 10.3389/fimmu.2020.00302

8,720 views
30 citations

Articles

Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies

Cost-effectiveness of degarelix versus LHRH agonists in prostate cancer: a systematic review

Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis

A Proof-of-Concept Clinical Trial of A Single Luteal Use of Long-Acting Gonadotropin-Releasing Hormone Antagonist Degarelix in Controlled Ovarian Stimulation for In Vitro Fertilization: Long Antagonist Protocol

Comparing the risk of cardiovascular disease between degarelix and gonadotropin-releasing hormone agonists:a systematic review and meta-analysis

Gender Disparity Impacts on Thymus Aging and LHRH Receptor Antagonist-Induced Thymic Reconstitution Following Chemotherapeutic Damage